Hematologic Malignancy
Acute Myeloid Leukemia with Genetic Abnormalities
CI-CAN-00004303Explore in graph →
Hematologic30 active trials2 approved drugs55 evidence items
- NCIt
- C224900
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004303Explore in graph →
Clinical trials
264 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (45)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05821738 | Avapritinib in CBF-AML With KIT Mutations | unknown | Phase 2 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT03624270 | Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia | unknown | Phase 2 | 60 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04689815 | Oral Arsenic Trioxide for NPM1-mutated AML | unknown | Phase 2 | 50 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05404516 | Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML | unknown | Phase 2 | 88 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT01064570 | AIDA 2000 Guidelines | unknown | Phase 2 | 600 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT01950611 | Proteasome Inhibition in Acute Promyelocytic Leukemia(PIAPL) | unknown | Phase 2 | 30 | Christian Medical College, Vellore, IndiaOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT00675870 | Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | unknown | Phase 2 | 65 | NuRx Pharmaceuticals, Inc.INDUSTRY | 1 | May 12, 2008 | clinicaltrials |
| NCT00517712 | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia(IAPLSG04) | unknown | Phase 2 / Phase 3 | 400 | Christian Medical College, Vellore, IndiaOTHER | 1 | Aug 17, 2007 | clinicaltrials |
Data updated 23 days agoSource updated May 9, 2023source: clinicaltrials